Search

Scientific Generics, the technology consultancy based in Cambridge, UK, has exported its 'Innovation Angels' methodology to Oslo in a pilot programme supported by the industrial development agency Innovation Norway.

The concept of angel investing - in which individuals devote both their time and money to nurturing young companies - has evolved over the past decade from an unknown or poorly understand phenomena in many parts of Europe to an established form of finance.

Venture capital firms used to moan that business angels were unprofessional and hard to work with. But Europe's new breed of angel investor networks appears anything but that, says Mary Lisbeth D'Amico

Marc Van Montagu, Europe's founding father of genetically modified crops and a powerful advocate for their acceptance in Europe, speaks to Science|Business News Editor Thomas Lau.

Lein Applied Diagnostics, a British company that develops blood glucose measuring for people with diabetes, has announced it has received further investment from its shareholder Seven Spires Investments. The company is seeking more investment to put a non-invasive blood glucose meter into clinical trials.

Spanish researchers have developed a technology that allows even the tone deaf to pick music with the right rhythm and tempo to keep the mass swaying.

The annual growth of biotech cultivation grew last year at its slowest pace since 1996, when biotech crops were first commercialised, according to a report by the International Service for the Acquisition of Agri-Biotech Applications, a non-profit group that advocates the use of bio-crops.

"With engineering I view this year's failure as next year's opportunity to try it again...." Gordon E. Moore, co-founded Intel in 1968

Micromet AG, a spin-off from the Institute for Immunology at Munich University, said it has agreed to grant four licenses of its single chain antibody technology to Abbott Laboratories, Alligator Bioscience AB, Haptogen Ltd. and an unnamed biopharmaceutical company, for the development of cancer treatments.

Lipoxen Plc, a drug spin-out company from the University of London's School of Pharmacy, said it has raised £3.78 million from a placing of 28 million shares for hiring news staff for preclinical trials to treat diabetes, Pneumococcal infections, and hepatitis C.